Table 4.

Risk factors to predict future disease relapse in EGPA

	Univariable analysis		Adjusted for prednisone and other immune medications
Predictor variable	Hazard ratio (95% CI)	P-value	Hazard ratio (95% CI)	P-value
BVAS/WG ≥1 defines disease relapse
Eos	1.01 (1.01, 1.02)	<0.01	1.01 (1.01, 1.02)	<0.01
IgE	0.98 (0.97, 1.03)	0.64	0.99 (0.97, 1.04)	0.53
ESR	1.23 (1.01, 1.42)	0.04	1.15 (0.99, 1.35)	0.12
CRP	1.04 (0.99, 1.17)	0.60	1.01 (0.98, 1.14)	0.58
Prednisone	1.16 (0.60, 2.34)	0.68
Other immune medications	0.45 (0.26, 0.79)	<0.01
BVAS/WG ≥3 defines disease relapse
Absolute eosinophil countEos	1.01 (1.01, 1.02)	<0.01	1.00 (1.00, 1.01)	0.25
IgE	0.99 (0.99, 1.00)	0.15	0.99 (0.99, 1.00)	0.49
ESR	1.64 (1.27, 1.75)	<0.01	1.52 (1.17, 1.67)	<0.01
CRP	1.01 (0.99, 1.03)	0.06	1.09 (0.99, 1.26)	0.28
Prednisone	1.37 (0.45, 3.22)	0.72
Other immune medications	0.76 (0.18, 0.92)	0.03

Risk ratios for Eos and IgE reported per 100 U increments. Risk ratios for ESR and CRP reported per 10 U increments.

BVAS/WG: BVAS for Wegener’s granulomatosis; EGPA: eosinophilic granulomatosis with polyangiitis; Eos: absolute eosinophil count.